Caplight Directory>Companies>EG 427-preview>Eg427


EG 427

EG 427

Private
ParisHealthcare & Life Scienceshttps://eg427.com/

Last Round

Series B

Feb 20, 2025

Total Funding Raised

$48.2M

Company Overview

EG 427 is a biotechnology company that develops pinpoint gene therapies designed to treat prevalent chronic diseases in neurology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Revenue Share

AI Layer

Non-AI

Keywords

gene therapynrHSV-1 vectorHERMES vector platformneurogenic detrusor overactivityNDOneurological diseasesneuro-urologyviral vectorone-time treatmentneurogenic bladderone-shot therapylocally-administered therapyclinical-stage biotechspinal cord injurySCImultiple sclerosisMSredosinglarge payload capacity

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EG 427 Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

EG 427 Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BFeb 20, 2025
Series A ExtensionJul 13, 2023
Series AMar 1, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

Philippe Chambon

Co-Founder, Chairman And CEO

Founding Team

Samuel Salot

Chief Operating Officer

Executive Team

EG 427 Investors

Notable investors and investment history

InvestorRounds
SCI VenturesSeries B
Andera PartnersSeries B
BpifranceSeries B
View all Investors

EG 427 Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EG 427 Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EG 427's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range26
Year Founded2019
Last FundingFeb 20, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.